ClinicalTrials.gg
CompletedNCT01555476Updated Jul 10, 2012

Study to Test the Blood to See if a New Medicine is Likely to Provide Pain Relief Similar to a Product Already Sold in Stores

A Phase 1 interventional study of Ibuprofen and Ibuprofen in Pain, sponsored by McNeil AB. Completed at 1 site in Sweden. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-07-10.

Sponsored by McNeil AB (formerly part of Johnson & Johnson) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 86 studies testing ibuprofen in Pain — 6 open to participants now, 6 under way, none of them phase 3. Ibuprofen · Pain.

Enrollment
71st of 86
32 · median 100
Started
2012
with 9 others
Phase 1
9 of 86
none open now
Registered
27th of 86
by date
Lead sponsor
2 of 86
McNeil AB

Among the 86 studies testing ibuprofen in Pain, this one is the 71st largest by enrollment, is one of 10 that started in 2012, is one of 9 in phase 1, and was the 27th registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.

Browse Pain studies →

Open to participants now

6 of the 86 studies testing ibuprofen in Pain are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About ibuprofen

Ibuprofen: first FDA approval 1974 (MOTRIN), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 86 studies testing ibuprofen in Pain, or all of them as a file.
02

Study summary

This study is designed to assess bioequivalence between one test and one reference formulation used for temporary relief of pain. The results will help decide if the new medicine is likely to provide pain relief similar to the product being sold.

Read the detailed description

The study is a single dose, randomized, two-way crossover study in 32 healthy male and female volunteers, minimum of 14 of each gender. Two doses of study medication will be given as single doses on two separate treatment visits. A washout of at least 48 hours will separate the treatment visits. Each visit will include an overnight fast at the clinic and 19 blood samples drawn for pharmacokinetic analyses. Tolerability of the treatments will be evaluated in terms of reported and observed adverse events (AE).

03

Conditions studied

  • Pain

Browse trials for

Keywords

  • Pharmacokinetics
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy (per protocol-specified parameters) male or female subjects (14 of each gender) between the ages of 18 and 50 years, inclusive.
  • Non- or ex-tobacco user, being defined as someone who completely stopped smoking or using any form of tobacco for at least 12 months before screening visit of this study.
  • For females: if not , agrees to use a protocol-specified means of or declared absence of sexual contact with a male partner during the study.
  • For males: No pregnant spouse or partner at screening and willingness to protect potential spouse or partner from becoming pregnant during the study.
  • (BMI) within protocol-specified parameters.
  • A personally signed and dated document indicating that the subject has been informed of all pertinent aspects of the study.
  • Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures specified in the protocol.

Exclusion criteria

Exclusion Criteria:

  • Evidence or history of an acute or chronic medical or psychiatric condition, laboratory abnormality, or drug use that, in the judgment of the investigator or an authorized physician, may compromise subject safety or the interpretation of results.
  • Females: Pregnant or breast-feeding
  • Treatment with an drug within 3 months preceding the first dose of study treatment.
  • History of regular alcohol consumption outside the protocol-specified allowances.
  • Donation or loss of blood within 3 months prior to the first treatment visit if the estimated lost blood volume equaled or exceeded 450 mL.
  • Relationship to persons involved directly with the conduct of the study, or their families.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    A-IBU

    A single 5 mL dose of 200 mg ibuprofen/5 mL experimental suspension, administered orally, with a 48-hour washout between visits.

    Drug: Ibuprofen

  • Active comparator
    B-IBU

    A single 5 mL dose of 200 mg ibuprofen/5 mL reference suspension, administered orally, with a 48-hour washout between visits

    Drug: Ibuprofen

Interventions

  • A single 5 mL dose of 200 mg ibuprofen/5 mL experimental suspension, administered orally, with a 48-hour washout between visits

    Also known as: Not yet marketed.

  • A single 5 mL dose of 200 mg ibuprofen/5 mL reference suspension, administered orally, with a 48-hour washout between visits

    Also known as: Nurofen for Children Six Plus

06

What researchers measure

Primary outcomes

  1. Cmax

    Maximum observed plasma concentration (Cmax), is the maximum (peak) concentration (amount of drug) measured in blood plasma after a dose administration.

    Time frame: During 12 hours post-dose

  2. AUCt

    Area under the plasma concentration-vs.-time curve from start of drug administration until last measured concentration (AUCt), is a measure of how much of the drug reaches the bloodstream during the sampling period.

    Time frame: During 12 hours post-dose

Secondary outcomes

  1. AUC∞

    Area under the plasma concentration-vs.-time curve from start of drug administration and extrapolated to infinity (AUC∞), is a measure of how much of the drug ever reaches the bloodstream.

    Time frame: During 12 hours post-dose

  2. tmax

    The time at which maximum concentration is reached (tmax)

    Time frame: During 12 hours post-dose

  3. Terminal Elimination Rate Constant (λz)

    The terminal elimination rate constant (λz) describes the rate at which a drug is eliminated from the body.

    Time frame: During 12 hours post-dose

  4. t½

    Terminal half-life (t½) is the time required for the plasma concentration (as well as the amount of drug in the body) to fall by one-half.

    Time frame: During 12 hours post-dose

  5. Mean Residence Time (MRT)

    Mean residence time (MRT) is the mean time a drug molecule resides in the body.

    Time frame: During 12 hours post-dose

07

Study locations

1 site
  • McNeil AB Clinical Pharmacology R&D
    Lund, 222 20, Sweden
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2012, a primary completion of Mar 2012 and a completion of Mar 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2012
First posted
Mar 15, 2012
Start
Feb 2012
Primary completionActual
Mar 2012
CompletionActual
Mar 2012
Last update
Jul 10, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01555476
Lead sponsor
McNeil AB
Responsible party
Sponsor
First posted
Mar 15, 2012
Start date
Feb 2012
Primary completion
Mar 2012
Completion
Mar 2012
Last update
Jul 10, 2012

Study contacts

Elisabeth Kruse, PhD
study director · McNeil AB

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibuprofen

Start the discussion